

29th December 2022

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that Cipla (EU) Limited, United Kingdom, (“Cipla EU”), wholly owned subsidiary of Cipla Limited, has entered into definitive agreements on 29th December 2022 for acquisition of ~10.35% of the registered share capital of Ethris GmbH, Germany.

Details required to be disclosed under the SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 have been provided in Annexure – I to this letter.

Please take the above information on record.

Thank you

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Simona Dsouza

Annexure – I

Details required to be disclosed as per SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	<p>Name of the target entity: Ethris GmbH (“Ethris”)</p> <p>Brief Details: Ethris, a limited liability company incorporated under the laws of Germany and registered with the commercial register of the local court of Munich under HRB 182200 is a pre-clinical stage firm working on a proprietary non-immunogenic mRNA platform.</p> <p>Turnover: EUR 5.45 million as on 31st December 2021.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>Acquisition does not fall within the purview of related party transactions.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs;	Research & Development (R&D) Industry: R&D of new therapeutic procedures and products for the treatment of acquired and congenital diseases.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Investment in Ethris will provide Cipla access to its mRNA platform and the mRNA-based products developed by Ethris
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
f)	Indicative time-period for completion of the acquisition;	The transaction is expected to get completed within 60 days from the date of signing of the agreement or such other time-period as may be mutually agreed between the parties in writing and shall be subject to completion of necessary regulatory formalities.

g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration.
h)	Cost of acquisition or the price at which the shares are acquired	Cipla EU to invest EUR 15 million for acquisition of 9,939 common shares of face value of EUR 1 each, for a stake of ~10.35% of the registered share capital of Ethris.
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief background: Please refer (a) above.</p> <p>Date of Incorporation: 26th October 2009</p> <p>History of last 3 years turnover: For the year ended: 31st December 2021: EUR 5.45 million 31st December 2020: EUR 16.82 million 31st December 2019: EUR 5.81 million</p> <p>Country: Germany</p>

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380